Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership

- Merck KGaA, Darmstadt, Germany, has entered into a strategic discovery research collaboration with C4 Therapeutics, Inc. (C4T) to develop two targeted protein degraders against critical oncogenic proteins within C4T's internal oncology pipeline.
- C4T will receive an upfront payment of $16 million and Merck KGaA will fund C4T's discovery research efforts.
- C4T is eligible for up to approximately $740 million in discovery, regulatory, and commercial milestone payments across the collaboration.
- C4T is also eligible for mid-single to low-double digit tiered royalties on future sales for each program.
- Merck KGaA will be responsible for clinical development and commercialization for drug candidates resulting from the collaboration.
- C4T will utilize its proprietary TORPEDO® platform to discover degraders targeting the partnership's oncogenic proteins of interest.

Forward-Looking Statements:

- The collaboration adds to Merck KGaA's growing portfolio of targeted protein degradation projects.
- The partnership aims to accelerate efforts to expand Merck KGaA's presence in the oncology market.

Forward Facts:

- The potential financial impact of the collaboration depends on the clinical success of the drug candidates, regulatory approvals, and market penetration post-commercialization.